doi: 10.1097/QAD.0000000000002188.
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy
Affiliations
- PMID: 30870194
- DOI: 10.1097/QAD.0000000000002188
Item in Clipboard
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy
AIDS.
.
Free article
Abstract
: We evaluated the efficacy and safety of a two-drug regimen including dolutegravir (DTG) and unboosted atazanavir (uATV) in 151 HIV-1 infected patients with HIV-RNA of more than 50 copies/ml. During a median follow-up of 62 (42-97) weeks, two virological failures (1%) and 13 treatment discontinuations (9%) occurred; the 48-week probability of virological failure was 0.8% (95% confidence interval 0.2-5.6%). Switch to DTG + uATV may represent a boosting and transcriptase reverse inhibitors sparing otion in individuals with long exposure to antiretroviral therapy and risk of cardiovascular disease.
Comment in
-
Response to letter to the editor: switch to dolutegravir and unboosted atazanavir.AIDS. 2019 Nov 15;33(14):2263-2264. doi: 10.1097/QAD.0000000000002330. AIDS. 2019. PMID: 31688044 No abstract available.
-
Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companion.AIDS. 2019 Nov 15;33(14):2264-2266. doi: 10.1097/QAD.0000000000002329. AIDS. 2019. PMID: 31688045 No abstract available.
-
Long-term safety and efficacy of dolutegravir and unboosted atazanavir among experienced HIV-infected adults.AIDS. 2019 Dec 1;33(15):2446-2447. doi: 10.1097/QAD.0000000000002365. AIDS. 2019. PMID: 31764113 No abstract available.
